Schizo Affective Disorder: Clinical Trials

11 trials for Schizo Affective Disorder, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 3 recruiting, 1 active not recruiting, 1 enrolling by invitation. 11 Phase 2, 4 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 211Completed 3, Recruiting 3, Active not recruiting 1, Enrolling by invitation 1, Suspended 1, Terminated 1, Withdrawn 1
Phase 14Recruiting 2, Completed 1, Suspended 1
Phase 31Active not recruiting 1

Follow Schizo Affective Disorder: new trials by email Literature Review of Schizo Affective Disorder trials Research Report on Schizo Affective Disorder

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Low Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy
Sigma-Stim, RUL LAP-ST (Low-Amplitude Pulse Seizure Therapy - Right Unilateral) - Suicidal Ideation, Major Depressive Disorder
Phase 2 / Phase 3Active not recruitingMichigan State University302024-07-032026-11-02
D-serine AudRem: R33 Phase
D-serine, Placebo - Schizophrenia, Schizo Affective Disorder
Phase 1 / Phase 2SuspendedNew York State Psychiatric Institute602022-12-012026-11-02
Rituximab Treatment for Psychosis And/or Obsessive Compulsive Disorder with Probable Immune System Involvement
Rituximab - Obsessive-Compulsive Disorder, Obsessive-Compulsive Behavior
Phase 2Enrolling by invitationUppsala University Hospital402022-05-012024-11-19
Acetazolamide for Treatment Resistant Schizophrenia
Acetazolamide, Placebo - Schizophrenia, Schizo Affective Disorder
Phase 1 / Phase 2RecruitingVishwajit Nimgaonkar, MD PhD602022-02-012026-07-07
Neurotransmitters in Treatment Resistant Schizophrenia Patients With add-on Sodium Benzoate
Sodium Benzoate 2gram/day, Placebo - Symptom, Cognitive, Schizophrenia
Phase 2RecruitingNational Cheng-Kung University Hospital902021-11-182026-06-16
Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders
Intranasal Insulin - Psychosis, Schizophrenia
Phase 2CompletedMclean Hospital872019-10-012026-09-03
L-arginine Study for Persistent Symptoms of Schizophrenia
L-arginine, Sapropterin Dihydrochloride - Schizo Affective Disorder, Schizophrenia
Phase 2WithdrawnUniversity of Massachusetts, Worcester2019-09-112022-01-20
Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia
Cromoglycate, Placebo - Schizophrenia, Schizo Affective Disorder
Phase 1 / Phase 2RecruitingVishwajit Nimgaonkar, MD PhD1602019-04-012026-03-19
D-serine Augmentation of Neuroplasticity
D-serine, Placebo - Schizophrenia, Schizo Affective Disorder
Phase 1 / Phase 2CompletedNew York State Psychiatric Institute452019-03-132022-06-14
Telmisartan Pilot Study on Treatment Resistant Schizophrenia
Telmisartan Pill - Schizophrenia, Schizo Affective Disorder
Phase 2TerminatedXiaoduo Fan62019-02-012022-03-02
Levetiracetam in Early Psychosis
Levetiracetam, Placebo - Psychosis, Schizophrenia
Phase 2CompletedNYU Langone Health482017-08-182022-11-21

Narrower conditions

Psychotic Disorders (11)  ·  Schizophrenia (10)  ·  Schizophrenia, Treatment-Resistant (2)  ·  Bipolar Disorder (1)  ·  Compulsive Behavior (1)  ·  Depression (1)  ·  Depressive Disorder, Major (1)  ·  Insulin Resistance (1)  ·  Mental Disorders (1)  ·  Neurobehavioral Manifestations (1)  ·  Obsessive-Compulsive Disorder (1)  ·  Schizophrenia, Paranoid (1)  ·  Suicidal Ideation (1)  ·  Suicide (1)

Broader conditions

Schizophrenia Spectrum and Other Psychotic Disorders (11)  ·  Mental Disorders (10)  ·  Behavior (2)  ·  Anxiety Disorders (1)  ·  Behavioral Symptoms (1)  ·  Bipolar and Related Disorders (1)  ·  Depressive Disorder (1)  ·  Glucose Metabolism Disorders (1)  ·  Hyperinsulinism (1)  ·  Impulsive Behavior (1)  ·  Metabolic Diseases (1)  ·  Mood Disorders (1)  ·  Nervous System Diseases (1)  ·  Neurologic Manifestations (1)  ·  Nutritional and Metabolic Diseases (1)

Interventions

Acetazolamide (1)  ·  Arginine (1)  ·  Cromolyn Sodium (1)  ·  Insulin (1)  ·  Levetiracetam (1)  ·  Rituximab (1)  ·  Telmisartan (1)  ·  sapropterin (1)

Sponsors

New York State Psychiatric Institute (2)  ·  Vishwajit Nimgaonkar, MD PhD (2)  ·  Mclean Hospital (1)  ·  Michigan State University (1)  ·  NYU Langone Health (1)  ·  National Cheng-Kung University Hospital (1)  ·  University of Massachusetts, Worcester (1)  ·  Uppsala University Hospital (1)  ·  Xiaoduo Fan (1)

Countries

United States (9)  ·  India (1)  ·  Sweden (1)  ·  Taiwan (1)

Top investigators

Donald Goff, MD (1)  ·  Janet L Cunningham, MD PhD (1)  ·  Nagy A Youssef, MD, PhD (1)  ·  Virginie-Anne Chouinard, M.D. (1)  ·  Vishwajit L Nimgaonkar, M.D., Ph.D. (1)  ·  Vishwajit L. Nimgaonkar, M.D., Ph.D. (1)  ·  Xiaoduo Fan (1)  ·  Xiaoduo Fan, MD, MPH (1)  ·  Yen-Kuang Yang, Dr (1)

Results publications

PMID 36958998, PMID 37293030, PMID 37690312

NIH funding

2019 (1), R33MH116093 (1)